Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the increasing number of immune diseases being treated with tumor necrosis factor-alpha (TNF-alpha) inhibitors will enable Amgen/Wyeth/Takeda's Enbrel (etanercept) and Abbott Laboratories/Eisai's Humira (adalimumab) to dominate this market for the next ten years.

Drugs that target TNF-alpha are among the most effective agents for treating a range of immune diseases including rheumatoid arthritis, psoriasis, and Crohn's disease.

The new Pharmacor report entitled TNF Alpha Inhibitors finds that expanding patient populations will be treated with etanercept and adalimumab for a number of diseases including psoriasis, psoriatic arthritis, and ulcerative colitis. Owing to the high price of these agents and their increased use in treatment, the market for TNF-alpha inhibitors will grow from $7.1 billion in 2005 to nearly $12 billion in 2014 in the United States, Western Europe, and Japan.

"Biologic agents targeting TNF-alpha first launched in 1998 for the treatment of rheumatoid arthritis and Crohn's disease and are now also used to treat psoriasis, psoriatic arthritis, and ulcerative colitis," said Cynthia Mundy, Ph.D., analyst at Decision Resources, Inc. "Although physicians were initially cautious about TNF-alpha inhibitors due to safety concerns, the availability of safety data over the past several years has provided reassurance that the benefits of TNF-alpha inhibitor therapy significantly outweighs the risks."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Generic Forms of Janssen's Risperdal and Pfizer's Geodon Not Expected to Increase Prescribing Habits in Antipsychotic Drug Market

View Now